Small Molecule Compound to Treat Neurological Diseases

­ Application Neurological disease treatment. Key Benefits Exemplary compound EU1180-490 is a potent and selective potentiator of GluN1/GluN3 NMDARs. The compound has excellent Lipinski drug-like properties including low molecular weight and…

Application
Neurological disease treatment.

Key Benefits

  • Exemplary compound EU1180-490 is a potent and selective potentiator of GluN1/GluN3 NMDARs.
  • The compound has excellent Lipinski drug-like properties including low molecular weight and cLogP, as well as water solubility.
  • The initial studies have determined that the compound can penetrate the blood-brain barrier.


Market Summary
Neurological disorders are a complicated study, and novel therapies, such as techniques described in this invention, are necessary for effective treatment. Moreover, neurology is a growing market. The global market for neurology should grow from $33.3 billion in 2019 to $39.4 billion by 2024 at a CAGR of 3.5%1. North America is estimated to hold the highest market share in the forecasted period, and of all neurological diseases, and psychiatric disorders have the highest forecasted market value at an expected $14.7 billion by 2024 at a CAGR of 1.8% from 2018-to 2024 (BCC Research PHM215A).

Technical Summary
Researchers have proposed a small molecule compound via the positive allosteric modulation of GluN1/GluN3A N-Methyl-D-Aspartate Receptors as a novel treatment for neurological diseases. Numerous neurological disorders and pathological conditions have displayed abnormal expressions and altered N-Methyl-D-aspartate receptor (NMDAR) function. Modulation of the GluN3A subunit of NMDAR receptors has been suggested to be neuroprotective, and influence synaptic development, plasticity, and place aversion conditioning. Researchers found that the compound EU1180-490 served as a potent and selective potentiator of the GluN1/GluN3 NMDARs, furthermore the compound has Lipinski drug-like properties such as low molecular weight/cLogP and high-water solubility.

Developmental Stage
Early-stage.

Website

https://emoryott.technologypublisher.com/techcase/20079

Contact Information

TTO Home Page: https://emoryott.technologypublisher.com

Name: Rajsekhar Guddneppanavar

Title: Licensing Associate

Email: RGUDDNE@emory.edu

Phone: 404-727-1185